An Infantile Bronchial Hemangioma Unresponsive to Propranolol Therapy

Sierpina, David; Chaudhary, Hamad M.; Walner, David L.; Aljadeff, Gabriel; DuBrow, Ira W.

doi:10.1001/archoto.2011.67

Cited by 9 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few PRIH cases have been reported and, unfortunately, few details about them were provided in the reports. Therefore, we cannot compare our observations.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Propranolol-resistant infantile haemangiomas

et al. 2013

View full text Add to dashboard Cite

Summary Backround Propranolol is now widely used to treat severe infantile haemangiomas (IHs). Very few cases of propranolol‐resistant IH (PRIH) are mentioned in the literature. Objectives To describe the characteristics of PRIHs. Methods A national, multicentre, retrospective, observational study was conducted from February 2011 to December 2011. All patients with PRIH evaluated by the members of the Groupe de Recherche Clinique en Dermatologie Pédiatrique from 1 January 2007 to 1 December 2011 were eligible. Results Among 1130 patients treated with propranolol for infantile haemangioma, 10 (0·9%) had PRIHs. Haemangioma propranolol resistance was observed at all ages during early childhood and at any proliferation stage. Conclusions PRIH is a rare phenomenon that raises questions and merits further investigation.

show abstract

“…Few PRIH cases have been reported and, unfortunately, few details about them were provided in the reports. Therefore, we cannot compare our observations.…”

Section: Discussionmentioning

confidence: 99%

“…Because we did not assess parents' therapeutic adherence, we cannot exclude that a treatment failure might have resulted from a lack of compliance. Few PRIH cases have been reported 3,15,[17][18][19][28][29][30][31] and, unfortunately, few details about them were provided in the reports. Therefore, we cannot compare our observations.…”

Section: Discussionmentioning

confidence: 99%

Propranolol-resistant infantile haemangiomas

et al. 2013

View full text Add to dashboard Cite

show abstract

“…317,[326][327][328][329][330] However, many clinicians have now reported success and low complication rates using propranolol in the management of airway IHs. 326,[331][332][333][334][335][336] Although the optimal dose and appropriate duration of therapy remain uncertain, most clinicians are dosing the drug as they would for cutaneous IH.…”

Section: Highlights Of This Sectionmentioning

confidence: 99%

Diagnosis and Management of Infantile Hemangioma

Darrow¹,

Mancini²,

Nopper³

et al. 2015

Pediatrics

211

290

View full text Add to dashboard Cite

Infantile hemangiomas (IHs) are the most common tumors of childhood. Unlike other tumors, they have the unique ability to involute after proliferation, often leading primary care providers to assume they will resolve without intervention or consequence. Unfortunately, a subset of IHs rapidly develop complications, resulting in pain, functional impairment, or permanent disfigurement. As a result, the primary clinician has the task of determining which lesions require early consultation with a specialist. Although several recent reviews have been published, this clinical report is the first based on input from individuals representing the many specialties involved in the treatment of IH. Its purpose is to update the pediatric community regarding recent discoveries in IH pathogenesis, treatment, and clinical associations and to provide a basis for clinical decision-making in the management of IH.

show abstract

“…Re-growth of IHs has been reported to occur 2–3 weeks after treatment suspension and usually responds to the re-introduction of propranolol [8, 34, 35]. A minimal improvement has been reported in several studies [36–41], but in most of these cases the hemangiomas were localized in internal organs other than the skin or the lesions were particularly wide.…”

Section: Discussionmentioning

confidence: 99%

Propranolol: Effectiveness and Failure in Infantile Cutaneous Hemangiomas

Praticò

Caraci

Pavone

et al. 2015

Drug Saf - Case Rep

View full text Add to dashboard Cite

Infantile hemangiomas (IHs) occur in early infancy and are considered to be one of the most frequent childhood tumors. Poor responsiveness to the treatment and complications are reported in about 10 % of patients. For years, the most common treatments for cutaneous and complicated IHs were corticosteroids, interferon-α, vincristine, laser therapy, or surgical intervention. More recently, treatment with propranolol has been reported with high success rates, both in the cutaneous and complicated form of IHs, and it is now considered to be the first-line treatment for IHs. Herein we report five cases of cutaneous IHs who presented at our unit between January 2011 and June 2012: in three of five patients, the lesion improved soon after the beginning of propranolol treatment; one case presented slow but complete resolution; and in one patient the treatment was unsuccessful. Patients who do not respond to propranolol have been seldom reported in the literature. However, the failure of propranolol treatment in childhood hemangiomas has been more frequent in our experience than that reported in previous case series. More attention should be given to the cases that poorly or negatively respond to treatment, and to the mechanisms underlying the failure to respond to treatment with propranolol.

show abstract

An Infantile Bronchial Hemangioma Unresponsive to Propranolol Therapy

Cited by 9 publications

References 15 publications

Propranolol-resistant infantile haemangiomas

Propranolol-resistant infantile haemangiomas

Diagnosis and Management of Infantile Hemangioma

Propranolol: Effectiveness and Failure in Infantile Cutaneous Hemangiomas

Contact Info

Product

Resources

About